Lung Transplant and Outcomes: A Single-Center Experience

DOI: 10.4236/ss.2012.36062   PDF   HTML     3,531 Downloads   5,742 Views   Citations

Abstract

Introduction: Lung transplant is the preferred treatment for several end-stage pulmonary diseases. The first successful human lung transplant was performed by the Toronto Group in 1983 [1]. Objectives: This article discusses our initial experience with single and double lung transplant. Study Design: A retrospective analysis was done on 11 consecutive lung transplants for end-stage pulmonary diseases performed at our institution between 2008 and 2010. Materials and Methods: Major indications were idiopathic pulmonary fibrosis (n = 6), bronchiectasis (n = 2), primary pulmonary hypertension (n = 1), lymphangioleiomyomatosis (n = 1), and scleroderma (n = 1). Results: Two patients (18.2%) died within 30 days of surgery. One- and 2-year survival rates for the recipients were 81.8% and 72.7%. Sepsis caused the deaths of 2 recipients. Conclusions: Although sepsis and chronic rejection limit the benefits, lung transplant gives many patients with end-stage pulmonary disease the ability for a better quality of life.

Share and Cite:

I. Al-Githmi, "Lung Transplant and Outcomes: A Single-Center Experience," Surgical Science, Vol. 3 No. 6, 2012, pp. 314-317. doi: 10.4236/ss.2012.36062.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] H. D. Hardy, “The First Lung Transplant in Man (1963) and the First Heart Transplant in Man (1964),” Transplant Proceedings, Vol. 31, No. 1, 1999, pp. 25-29. doi:10.1016/S0041-1345(98)02059-4
[2] Toronto Lung Transplant Group, “Unilateral Lung Transplantation for Pulmonary Fibrosis,” New England Journal of Medicine, Vol. 314, 1986, pp. 1140-1145. doi:10.1056/NEJM198605013141802
[3] C. Aigner and W. Klepetko, “Lung Transplantation: State of the Art,” Journal of Cardiovascular Surgery, Vol. 6, 2002, pp. 22-28.
[4] J. D. Hosenpud, L. E. Bennet, M. K. Berkeley, et al., “The Registry of International Society for Heat and Lung Transplantation: Eighteen Official Report-2001,” Journal of Heart and Lung Transplantation, Vol. 20, No. 8, 2001, pp. 805-815. doi:10.1016/S1053-2498(01)00323-0
[5] S. M. Arcasoy and R. M. Kotloff, “Lung Transplantation,” New England Journal of Medicine, Vol. 340, 1999, pp. 1081-1091. doi:10.1056/NEJM199904083401406
[6] K. Bando, J. M. Armitage, I. L. Paradis, et al., “Indications for and Results of Single, Bilateral and Heart-Lung Transplantation for Pulmonary Hypertension,” Journal of Thoracic and Cardiovascular Surgery, Vol. 108, 1994, pp. 1056-1065.
[7] J. N. Rao, A. Hasan, G. Parry, et al., “Routine Cardiopulmonary Bypass (CPB) for Bilateral Lung Transplantation,” Abstract Presented at 14th Annual Meeting of EACTS, Frankfurt, 7-11 October 2000.
[8] M. de Perrot, C. Chaparro, K. McRae, et al., “Twenty Year Experience of Lung Transplantation at a Single Center: Influence of Recipient Diagnosis on Long-Term Survival,” Journal of Thoracic and Cardiovascular Surgery, Vol. 127, No. 5, 2004, pp. 1493-1501. doi:10.1016/j.jtcvs.2003.11.047
[9] E. .P Trulock, “Lung Transplantation,” American Journal of Respiratory and Critical Care Medicine, Vol. 155, No. 3, 1997, pp. 789-818.
[10] R. E. Girgis, H. Reichenspmer, R. C. Robbins, et al., “Utility of Annual Surveillance Bronchoscopy in Heart-Lung Transplant Recipients,” Transplantation, Vol. 160, 1995, pp. 1458-1461. doi:10.1097/00007890-199560120-00015
[11] S. Kesten, D. Chamberlain and J. Maurer, “Yield of Surveillance Trans-Bronchial Biopsies Performed beyond Two Years after Lung Transplantation,” Journal of Heart and Lung Transplant, Vol. 15, 1996, pp. 384-388.
[12] I. Al-Githmi, N. Batawil, N. Shigemura, et al., “Bronchiolitis Obliterans Following Lung Transplantation,” European Journal Cardio-Thoracic Surgery, Vol. 30, No. 6, 2006, pp. 846-851. doi:10.1016/j.ejcts.2006.09.027

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.